Teva's Growth Profile Looks Strong From Innovative Portfolio, Biosimilar Approvals and Deep Pipeline
We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...
Hosted on MSN3d
Robert Half Earnings Transcript (NYSE:RHI)
Presentation Operator Please standby. Hello, and welcome to the Robert Half 4th-Quarter 2024 Conference Call. Today's conference call is being recorded. If you'd like to ask a question during the Q&A ...